Bellevue Group AG Sells 84,994 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Bellevue Group AG lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 65.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 44,833 shares of the medical research company’s stock after selling 84,994 shares during the quarter. Bellevue Group AG’s holdings in IQVIA were worth $8,810,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Synergy Asset Management LLC acquired a new position in IQVIA during the fourth quarter worth $33,000. GKV Capital Management Co. Inc. acquired a new stake in shares of IQVIA in the fourth quarter valued at about $39,000. Lee Danner & Bass Inc. bought a new stake in IQVIA during the fourth quarter worth about $44,000. Zions Bancorporation N.A. raised its holdings in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after acquiring an additional 85 shares in the last quarter. Finally, Versant Capital Management Inc grew its stake in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 93 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Up 1.5 %

IQV opened at $153.42 on Friday. The stock has a fifty day moving average of $167.52 and a 200-day moving average of $191.06. The company has a market capitalization of $27.05 billion, a P/E ratio of 20.46, a P/E/G ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a fifty-two week low of $135.97 and a fifty-two week high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on IQV shares. Morgan Stanley upped their price objective on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Robert W. Baird dropped their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. BTIG Research downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Stifel Nicolaus dropped their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, HSBC cut IQVIA from a “buy” rating to a “hold” rating and reduced their price target for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $237.62.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.